Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Conditions
Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University of Miami, Miami, Florida, United States
Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
Memorial Sloan Kettering Commack, Commack, New York, United States
Memorial Sloan Kettering Westchester, Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Contact: Principal Investigator (Allison Moskowitz, MD)Weill Cornell Medical College, New York, New York, United States
Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, United States
Study leads
Alison Moskowitz, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center